However, conventional predictive methods, encompassing tumour pathology, tumour staging systems, and PLD-1 expression levels, have proven ineffective in accurately predicting the response to antitumour immunotherapy (Squamous cell lung cancer). Here, PLD1 is linked to squamous cell lung carcinoma.